Treatment of Osteosarcoma and UPS of Bone With Metastatic Disease at Diagnosis

Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 2, 2024 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Approximately 20% to 25% of patients with osteosarcoma present with clinically detectable metastatic disease. For patients with metastatic disease at initial presentation, roughly 20% will remain continuously free of disease, and roughly 30% will survive 5 years from diagnosis.[1]

Source links and citations

The lungs are the most common site of initial metastatic disease.[2] Patients with metastases limited to the lungs have a better outcome than do patients with metastases to other sites or to the lungs combined with other sites.[1,3]

Source links and citations

Continue within this section

Treatment Options for Osteosarcoma and UPS of Bone With Metastatic Disease at Diagnosis →Treatment Options for Lung-Only Metastases at Diagnosis →Treatment Options for Bone Metastases With or Without Lung Metastases →Treatment Options Under Clinical Evaluation →

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice